Neurimmune announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform. Ono will be exclusively responsible for worldwide development and marketing of products. Neurimmune will receive an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales.
“We are excited to partner with Ono, a global pioneer of innovative medicines,” said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “This new collaboration serves our commitment to patients to fully leverage our RTM™ technology for the discovery and development of breakthrough medicines in areas of high unmet medical need.”
“Ono identified Neurimmune as the partner of choice for the generation of leads for a target in our portfolio,” said Hiromu Habashita, Ph.D., Corporate Officer and Executive Director, Discovery and Research of Ono. “We are excited to work with Neurimmune on identifying and developing the next generation of innovative treatments in neurodegenerative disease area.”